Levosimendan inhibits HIV-1 infection in myeloid cells in the RIOK1-dependent manner

This study demonstrates that the heart failure drug levosimendan effectively inhibits HIV-1 infection and reactivation in various myeloid cells through a mechanism dependent on the serine/threonine kinase RIOK1, positioning it as a promising agent for block-and-lock strategies targeting myeloid viral reservoirs.

The Gist

The Big Problem: The "Sleeping" Virus

Imagine your body is a fortress. For years, doctors have had a powerful weapon against HIV (the virus that causes AIDS) called antiretroviral therapy (cART). This weapon is like a high-tech security system that keeps the intruder (HIV) locked out of the main rooms, so the patient feels fine and the virus is undetectable in their blood.

However, the virus is sneaky. It doesn't just hide in the main rooms (immune cells called T-cells); it also burrows into the basement and the walls (cells called myeloid cells, like macrophages and microglia). Once there, it goes into a deep sleep, becoming a "silent reservoir." Even if you take your medicine, the virus is still there, waiting. If you stop the medicine, the virus wakes up and attacks again.

Scientists have been trying two main strategies to cure this:

1. "Shock and Kill": Wake the virus up so the immune system can see it and destroy it. (This hasn't worked well yet because the virus is too good at hiding, and waking it up can be dangerous).
2. "Block and Lock": Instead of waking it up, find a way to permanently lock the door so the virus stays asleep forever. This is the goal of this new study.

The Hero: A Heart Drug with a Secret Superpower

The researchers were looking for a drug that could act as a "Block and Lock" agent. They found a candidate: Levosimendan (LSM).

• What is it? LSM is an existing, FDA-approved drug used to treat heart failure. Think of it as a mechanic that helps a tired heart pump stronger.
• The Discovery: The researchers found that this heart drug has a secret superpower: it can also act as a super-lock for HIV in the "basement" cells (myeloid cells).

How the Experiment Worked (The "Test Drive")

The team tested this drug on various types of "basement" cells in the lab:

• Microglia: The brain's security guards.
• Kupffer Cells: The liver's cleanup crew.
• Macrophages: The body's general cleanup crew.

The Results:
When they added LSM to these cells, the virus tried to wake up (reactivate), but LSM slammed the door shut.

• Analogy: Imagine the virus is a mischievous kid trying to turn on the lights in a dark room. LSM is like a heavy-duty padlock on the light switch. No matter how much the kid pushes, the lights stay off.
• Safety: The best part? The drug didn't hurt the cells. It was like a gentle lock that stopped the virus without damaging the house.

The Secret Mechanism: The "Master Key" (RIOK1)

The researchers wanted to know how LSM was doing this. They discovered it works by targeting a specific protein inside the cell called RIOK1.

• The Analogy: Think of RIOK1 as a Master Key that the virus uses to unlock its own dormancy and start replicating.
• The Action: LSM acts like a glue that gets stuck in the keyhole of the Master Key (RIOK1).
• The Result: The virus tries to use the key, but it's stuck. It can't turn, it can't unlock the door, and it stays asleep.
• Proof: When the researchers added extra Master Keys (overexpressed RIOK1) to the cells, the virus woke up again. But when they added the LSM glue, the extra keys got stuck, and the virus went back to sleep. This proved that LSM works specifically by jamming this specific key.

Why This Matters

1. Broad Protection: Most previous drugs only worked on T-cells. This drug works on the "basement" cells (myeloid cells) where the virus hides deep in the brain and liver.
2. Anti-Inflammation: HIV causes chronic inflammation (like a constant, low-grade fire in the body). LSM also helps put out this fire, making the patient feel better overall.
3. Ready to Go: Since LSM is already approved for heart patients, it is safe and known. It could potentially be repurposed quickly to help HIV patients, moving from the heart clinic to the HIV clinic.

The Bottom Line

This study suggests that a drug currently used to help failing hearts might also be the key to permanently silencing HIV in the body's most stubborn hiding spots. By jamming a specific cellular "key" (RIOK1), Levosimendan could help achieve a "functional cure," where the virus is locked away so tightly that patients might one day live without needing daily medication.

Technical Summary

1. Problem Statement

Despite the success of combination antiretroviral therapy (cART) in suppressing viral load, a definitive cure for HIV-1 remains elusive due to the persistence of stable viral reservoirs. While CD4+ T cells are the primary focus of reservoir research, myeloid cells (including circulating monocytes, tissue-resident macrophages, and microglia) serve as critical, long-lived reservoirs that are resistant to cART and HIV-induced cytopathic effects.

• The "Block and Lock" Strategy: Current cure strategies often rely on "shock and kill" (reactivating and clearing), which poses safety risks, particularly in the Central Nervous System (CNS). An alternative "block and lock" approach aims to use Latency-Promoting Agents (LPAs) to permanently silence proviruses.
• The Gap: Most LPAs have been tested primarily in CD4+ T cells. Their efficacy in myeloid cells is largely unknown, and there is a need for safe, potent agents that can target these diverse reservoirs to achieve a functional cure.

2. Methodology

The study employed a multi-model approach to evaluate the anti-HIV potential of Levosimendan (LSM), an FDA-approved drug for heart failure, focusing on myeloid cells.

• Cell Models:
  • Latent Cell Lines: HC69 (microglia), THP89GFP, and U1 (monocytic) cells infected with HIV-1 constructs containing GFP reporters.
  • Primary & Differentiated Cells:
    • iPSC-derived Microglia (iMG): Differentiated from human induced pluripotent stem cells to model CNS reservoirs.
    • Human Primary Kupffer Cells (KC): Liver-resident macrophages.
    • Human Monocyte-Derived Macrophages (MDMs): Differentiated from peripheral blood monocytes.
• Experimental Design:
  • Reactivation Assays: Cells were treated with TNFα to induce lytic reactivation, followed by LSM treatment to measure inhibition of GFP expression or viral gene transcription.
  • Infection Assays: Cells were either pre-treated with LSM before HIV-1 infection (prevention) or treated post-infection (suppression).
  • Mechanistic Studies:
    • Overexpression: Transfection of V5-tagged RIOK1 (a predicted LSM target kinase) to test if it reverses LSM's effects.
    • Molecular Analysis: RT-qPCR for viral transcripts (Tat, Gag) and host immune genes (IL-1β, Viperin, IFIT1); Western blotting for viral proteins (p24) and markers; Flow cytometry for reactivation rates.
  • Toxicity: Cell viability was assessed via CellTiter-Glo and MTT assays to determine IC50 (inhibitory concentration) vs. LC50 (lethal concentration).

3. Key Contributions

• Repurposing LSM: Identified Levosimendan, a calcium sensitizer used for heart failure, as a potent LPA effective against HIV-1 in myeloid cells, extending its known efficacy beyond CD4+ T cells.
• Mechanistic Insight: Established that LSM's anti-HIV activity is RIOK1-dependent. The study demonstrates that overexpression of RIOK1 (RIO kinase 1) overcomes LSM's inhibitory effects, confirming RIOK1 as a critical host factor for HIV-1 transcription in these cells.
• Broad Applicability: Validated LSM's efficacy across a spectrum of myeloid models, including iPSC-derived microglia and primary human macrophages (Kupffer cells and MDMs), addressing the limitations of cell line-only studies.
• Dual Mechanism: Revealed that LSM not only directly suppresses proviral transcription but also upregulates host antiviral innate immune genes (e.g., Viperin, IFIT1) and reduces pro-inflammatory cytokines (e.g., IL-1β).

4. Key Results

• Inhibition of Reactivation: LSM significantly reduced TNFα-induced HIV-1 lytic reactivation in HC69, THP89GFP, and U1 cells.
  • IC50 Values: ~6.85 µM (HC69), ~7.70 µM (THP89GFP), and ~8.30 µM (U1).
  • Selectivity: LSM showed low cytotoxicity; LC50 values were significantly higher than IC50 values (e.g., LC50 for HC69 was 27.47 µM, while IC50 was 6.85 µM).
• Suppression in Primary Models:
  • iMGs: LSM suppressed HIV-1 Tat, Gag, and IL-1β expression.
  • Kupffer Cells: LSM reduced p24 protein and viral transcripts.
  • MDMs: LSM blocked acute infection (pre-treatment) and suppressed established infection (post-treatment), preventing syncytia formation.
• RIOK1 Dependency:
  • Overexpression of RIOK1 enhanced HIV-1 reactivation and infection.
  • Crucially, LSM treatment abolished the enhancing effects of RIOK1 overexpression, confirming that LSM acts by inhibiting RIOK1 function.
• Immune Modulation: LSM treatment in MDMs led to the upregulation of interferon-stimulated genes (ISGs) like Viperin and IFIT1, suggesting an indirect mechanism of action via innate immune activation.

5. Significance

• Therapeutic Potential: LSM represents a promising candidate for a "block and lock" HIV cure strategy, specifically targeting the often-overlooked myeloid reservoirs (microglia and macrophages) that sustain chronic inflammation and viral persistence.
• Safety Profile: As an existing drug with a known safety profile in humans (used for acute heart failure), LSM could accelerate the timeline for pre-clinical and clinical trials compared to novel compounds.
• Novel Target Discovery: The study identifies RIOK1, a kinase involved in ribosome biogenesis, as a previously unappreciated host regulator of HIV-1 transcription. This opens new avenues for understanding HIV latency mechanisms and developing specific kinase inhibitors.
• Dual Benefit: LSM's ability to simultaneously suppress viral replication and reduce HIV-associated chronic inflammation (via NF-κB inhibition and cytokine reduction) offers a dual therapeutic advantage for treating HIV-1 and its comorbidities.

Conclusion: The authors conclude that Levosimendan is a potent, RIOK1-dependent latency-promoting agent capable of inhibiting HIV-1 infection and reactivation in myeloid cells, warranting further investigation as a component of a functional HIV cure.